Some Medicare Part D-covered drugs that appear to be candidates for the initial round of federal government price negotiation under pending legislation may already have net prices (after rebates) that are below the maximum average manufacturer prices set by the bill. So in the end, they may not be subject to further price cuts.
Implementation of price discounts mandated by the Health and Human Services Department in a process described as “negotiation” is scheduled...






